NSCLC, FDA and Tagrisso
AstraZeneca’s Tagrisso gains FDA approval for stage III NSCLC
Tagrisso, which targets exon 19 deletions or exon 21 (L858R) mutations, received the approval following a priority review.
Tagrisso Approved for Stage III Unresectable EGFR-Mutated NSCLC
FDA has approved Tagrisso for the treatment of adult patients with locally advanced, unresectable NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy.
AZN's Tagrisso Gets FDA Nod for Expanded Use in NSCLC
AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Tagrisso (osimertinib) for expanded use in lung cancer. The regulatory body has approved Tagrisso for the treatment of unresectable,
AstraZeneca’s Tagrisso approved by FDA to treat EGFR-mutated lung cancer
Tagrisso (osimertinib) has been approved by the US Food and Drug Administration (FDA) to treat a new subset of lung cancer patients. The epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor has been specifically authorised to treat unresectable,
FDA Approves Tagrisso for Some With Advanced NSCLC
Tagrisso has been approved for some adults with locally advanced, unresectable stage 3 non-small cell lung cancer.
AstraZeneca gets FDA expanded approval for Tagrisso
AstraZeneca (NASDAQ:AZN) has received FDA approval for its drug Tagrisso for the treatment of patients with unresectable Stage 3 EGFR-mutant non-small cell lung cancer, or NSCLC. The agency approved Tagrisso,
pharmaphorum5d
AZ gets sought-after lung cancer approval for Tagrisso
AstraZeneca's EGFR inhibitor Tagrisso has been approved by the FDA for a new lung cancer indication that could make it a ...
Cure Today2h
Oncology Drugs Approved by the FDA in September 2024
Throughout September, the FDA approved drugs for the treatment of diseases including lung cancer, multiple myeloma, thyroid ...
FiercePharma5d
AstraZeneca’s Tagrisso follows up ASCO standing ovation with lung cancer FDA nod
In June, at the American Society of Clinical Oncology (ASCO) conference in Chicago, when AstraZeneca discussed results from a ...
AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication
The FDA has approved AstraZeneca's Tagrisso for treating unresectable, Stage III EGFR-mutated non-small cell lung cancer, ...
Business Wire5d
TAGRISSO ® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
--(BUSINESS WIRE)--AstraZeneca’s TAGRISSO ® (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm ...
London South East5d
Tagrisso US approval in unresectable lung cancer
Tagrisso is currently under review with regulatory authorities in other countries around the world for this indication. Each year, an estimated 2.4 million people are diagnosed with lung cancer ...